Cepheid Shares Hit 52-Week High | GenomeWeb
Shares of Cepheid hit a 52-week high of $20.29 on Tuesday before closing at $20.17. The stock led all gainers in the BCW Index for the three-week period ended Tuesday, up 19.4 percent (BioCommerce Week did not publish the past two weeks and the last Index ran on Aug. 15). Cepheid signed an anthrax test agreement with the US Postal Service in mid-August worth a potential $200 million to the firm (see Briefs).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.